At the time of writing, TG Therapeutics Inc [TGTX] stock is trading at $31.13, up 1.10%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TGTX shares have gain 1.73% over the last week, with a monthly amount glided 1.43%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On October 29, 2024, TD Cowen initiated with a Buy rating and assigned a price target of $50 on the stock. Goldman upgraded its rating to a Neutral and decreased its price target to $12 on August 02, 2023. BofA Securities started tracking with a Underperform rating for this stock on May 20, 2022, and assigned it a price target of $5. In a note dated February 23, 2022, B. Riley Securities reiterated a Buy rating on this stock and revised its target price from $49 to $35.
For the past year, the stock price of TG Therapeutics Inc fluctuated between $25.28 and $46.48. Currently, Wall Street analysts expect the stock to reach $60 within the next 12 months. TG Therapeutics Inc [NASDAQ: TGTX] shares were valued at $31.13 at the most recent close of the market. An investor can expect a potential return of 92.74% based on the average TGTX price forecast.
Analyzing the TGTX fundamentals
According to TG Therapeutics Inc [NASDAQ:TGTX], the company’s sales were 531.90M for trailing twelve months, which represents an 92.79% jump. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at 0.19%, Pretax Profit Margin comes in at 0.15%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.09, Equity is 0.26 and Total Capital is 0.16. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.92.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 30.60 points at the first support level, and at 30.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.55, and for the 2nd resistance point, it is at 31.97.
Ratios To Look Out For
It is important to note that TG Therapeutics Inc [NASDAQ:TGTX] has a current ratio of 3.82. Also, the Quick Ratio is 2.89, while the Cash Ratio stands at 0.75. Considering the valuation of this stock, the price to sales ratio is 9.29, the price to book ratio is 7.96 and price to earnings (TTM) ratio is 11.21.
Transactions by insiders
Recent insider trading involved Echelard Yann, Director, that happened on Nov 24 ’25 when 5000.0 shares were sold. Director, Echelard Yann completed a deal on Nov 24 ’25 to buy 5000.0 shares. Meanwhile, Director Lonial Sagar sold 20852.0 shares on Sep 11 ’25.
